Olympian Sydney McLaughlin-Levrone is letting track take a backseat [USA TODAY]
Cytokinetics, Incorporated (CYTK)
Last cytokinetics, incorporated earnings: 3/3 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cytokinetics.com/investor-overview
Company Research
Source: USA TODAY
time in the 400-meter hurdles to claim gold in the event at the 2024 Paris Olympics and won her first world title in the 400-meter flat at the 2025 World Championships. In January, the four-time Olympic gold medalist announced that she is pregnant and expecting her first child with husband Andre Levrone Jr. this summer, which means a break from record chasing – for now. "Track and field is taking the backseat in my life for the first time in a long time, which I'm really excited about," McLaughlin-Levrone said Tuesday, Jan. 26, in an interview with USA TODAY. She'll continue to train while pregnant for as long as she safely can, though competing in the World Athletics Ultimate Championships in September is probably "not in the cards" anymore, she said. Regardless, McLaughlin-Levrone said she is prioritizing a healthy pregnancy and time with her family before her attention turns to preparations for the 2028 Los Angeles Olympics. The shift also allows McLaughlin-Levrone to focus
Show less
Read more
Impact Snapshot
Event Time:
CYTK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYTK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYTK alerts
High impacting Cytokinetics, Incorporated news events
Weekly update
A roundup of the hottest topics
CYTK
News
- Cytokinetics' heart drug hits market after FDA approval [FOX Business Network]FOX Business Network
- Cytokinetics (NASDAQ:CYTK) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $87.00 price target on the stock.MarketBeat
- How MYQORZO's REMS-Restricted U.S. Launch Will Impact Cytokinetics (CYTK) Investors [Yahoo! Finance]Yahoo! Finance
- Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)GlobeNewswire
- Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and SymptomsGlobeNewswire
CYTK
Earnings
- 11/5/25 - Miss
CYTK
Sec Filings
- 1/20/26 - Form 4
- 1/16/26 - Form 4
- 1/16/26 - Form 4
- CYTK's page on the SEC website